BioStem Technologies, Inc. - SIC # 5122 - DRUGS, DRUG PROPRIETARIES, AND DRUGGISTS SUNDRIES

Ticker Exchange SIC # Website Latest Ticker
BSEM Over the counter 5122 www.biostemtechnologies.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioStem Technologies, Inc.

BSEM Continues to Excel - Feb 24th, 2025 12:41 pm
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers - Feb 24th, 2025 12:00 pm
BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million - Jan 13th, 2025 12:00 pm
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje® - Jan 8th, 2025 12:00 pm
BioStem Technologies CEO to Present at Biotech Showcase 2025 - Jan 2nd, 2025 12:00 pm
Kane Biotech Reports Change in U.S. Distribution Partner for revyve Gel - Nov 27th, 2024 4:03 pm
BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts - Nov 25th, 2024 12:00 pm
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global - Nov 20th, 2024 12:00 pm
BSEM: Medicare Issues Shouldn’t Impact BioStem - Nov 15th, 2024 4:05 pm
BSEM Continues to Exceed Expectations - Nov 13th, 2024 9:00 am
BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million - Nov 12th, 2024 12:29 pm
BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions - Oct 29th, 2024 11:00 am
BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - Oct 28th, 2024 5:58 pm
BioStem Technologies to Present at the LD Micro Main Event XVII on Wednesday, October 30, 2024, at 9:30 AM PT - Oct 23rd, 2024 11:00 am
BSEM Announces Expanding Market and Stellar Test Results - Oct 17th, 2024 11:16 am
BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment - Oct 17th, 2024 11:00 am
BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions - Oct 15th, 2024 11:00 am
BSEM Initiates Trial and Start Uplisting Process - Oct 2nd, 2024 12:26 pm
BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers - Oct 2nd, 2024 11:00 am
BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting - Sep 30th, 2024 11:00 am